Scholarlink

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a debilitating and chronic multisystem illness with an unknown etiology. Immune dysfunction, energy metabolism and mitochondrial abnormalities, and chronic neuroinflammation have been recognized as crucial key pathogenesis in the perpetuation of ME/CFS. Nicotinamide adenine dinucleotide (NADH), a reduced form of coenzyme I, with the properties of enhancing mitochondrial function as a bioenergy cofactor, scavenging free radicals, and antioxidant, is considered a candidate drug for the treatment of CFS. Several clinical trials have demonstrated the potential for NADH to improve symptoms in patients with CFS. CoQ10 and NADH combined supplementation may be a better safer treatment option for CFS.

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Coenzyme I and Chronic Fatigue Syndrome

  • 章节

  • 发表日期：

    2025年

查看全文
  • Shan-Yao Pan,
  • Li Luo

摘要

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a debilitating and chronic multisystem illness with an unknown etiology. Immune dysfunction, energy metabolism and mitochondrial abnormalities, and chronic neuroinflammation have been recognized as crucial key pathogenesis in the perpetuation of ME/CFS. Nicotinamide adenine dinucleotide (NADH), a reduced form of coenzyme I, with the properties of enhancing mitochondrial function as a bioenergy cofactor, scavenging free radicals, and antioxidant, is considered a candidate drug for the treatment of CFS. Several clinical trials have demonstrated the potential for NADH to improve symptoms in patients with CFS. CoQ10 and NADH combined supplementation may be a better safer treatment option for CFS.